Cite
HARVARD Citation
Gordon, K. et al. (2022). Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. Journal of dermatological treatment. pp. 219-228. [Online].